Researchers from SL Bigen Inc. and collaborators presented the preclinical characterization of BM-205, a novel entity of engineered MSCs designed to exert antitumor functions.
Arovella Therapeutics Ltd. is heading toward the clinic with its lead product, ALA-101, which consists of a chimeric antigen receptor (CAR) targeting CD19 and invariant natural killer T (iNKT) cells.
Compared to normal tissues, where the expression of ULBP2/5/6 protein is restricted, in non-small-cell lung cancer (NSCLC), head and neck cancer and squamous urothelial carcinoma, the levels of ULBP2/5/6 remain high even following relapse from standard-of-care therapies and is retained in metastatic lesions. Besides, these squamous cell cancers showed a high proportion of CD2+ tumor-infiltrating lymphocytes compared to other co-stimulatory receptors.
Researchers from Astrazeneca plc presented the discovery and preclinical characterization of AZD-9793, a novel CD8-guided T-cell engager (TCE) being developed for the treatment of hepatocellular carcinoma (HCC).
Hemogenyx Pharmaceuticals plc has obtained approval by the institutional review board (IRB) of the company’s first clinical site to initiate a phase I trial of the company’s lead asset, HEMO-CAR-T, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults.
Researchers from Caedo Oncology AS presented the discovery and preclinical characterization of CO-005, a novel anti-CD47 fusion protein being developed for the treatment of lymphoma.
Adcendo ApS has closed an oversubscribed $135 million series B financing round to support its development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need.
Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.
A team from Nanjing Leads Biolabs Co. Ltd. presented the discovery and preclinical characterization of LBL-042, a novel bispecific antibody designed to simultaneously target PD-1 and LILRB1/2, with the aim of improving immune evasion of tumor microenvironment and potentially overcoming resistance to immuno-oncology therapy.
RSS
